p53 inactivation by MDM2 and MDMX negative feedback loops in testicular germ cell tumors

• Published in: Cell cycle (Georgetown, Tex.) Vol. 9; no. 7; pp. 1411 - 1420
• Main Authors: Li, Baozong, Cheng, Qian, Li, Zhenyu, Chen, Jiandong
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 01.04.2010
• Subjects: Binding; Biology; Bioscience; Blotting, Western; Calcium; Cancer; Cell; Cell Line, Tumor; Chromatin Immunoprecipitation; Cycle; Humans; Landes; Male; Neoplasms, Germ Cell and Embryonal - metabolism; Nuclear Proteins - genetics; Nuclear Proteins - metabolism; Organogenesis; Polymerase Chain Reaction; Proteins; Proto-Oncogene Proteins - genetics; Proto-Oncogene Proteins - metabolism; Proto-Oncogene Proteins c-mdm2; RNA Interference; Testicular Neoplasms - genetics; Testicular Neoplasms - metabolism; Tumor Suppressor Protein p53 - genetics; Tumor Suppressor Protein p53 - metabolism
• ISSN: 1538-4101; 1551-4005
• DOI: 10.4161/cc.9.7.11255

Testicular germ cell tumors (TGCT) are unique in their excellent response to DNA-damaging chemotherapy. Mutation of p53 is rare in both untreated and relapsed TGCTs, suggesting that p53 fails to respond effectively against malignant transformation in germ cells. Previous studies implicated the presence of a poorly defined TGCT-specific mechanism of p53 inactivation. Here we show that disruption of p53-MDM2 binding using the MDM2-specific inhibitor Nutlin activates p53 in TGCT cells and is sufficient to induce strong apoptosis. Knockdown of MDMX cooperates with Nutlin to activate p53. Surprisingly, we found that p53 activation induced a two-fold increase in MDMX mRNA and protein expression in TGCT cells. A p53-responsive promoter is identified in MDMX intron 1 that contains a functional p53-binding site, suggesting that MDMX also functions as a negative feedback regulator of p53 in a cell line-dependent fashion. These findings suggest that MDM2 and MDMX are responsible for the functional inactivation of p53 in TGCT. Furthermore, TGCT cells are unique in having a strong apoptosis response to p53. Direct activation of p53 by targeting MDM2 and MDMX may provide a backup approach for the treatment of TGCTs resistant to DNA-damaging drugs.